Respectfully, I think you have this backwards. The lack of a clinical benefit in the AIM-HIGH study reduces the likelihood that AMRN’s outcomes study for AMR-101 will turn out positive, and this lessens the value of the AMR-101 program to potential suitors.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.